Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness

Background: When treatment-refractory schizophrenia shows an insufficient response to a trial of clozapine, clinicians commonly add a second antipsychotic, despite the lack of robust evidence to justify this practice. Objectives: The main objectives of the study were to establish the clinical effect...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Thomas RE Barnes, Verity C Leeson, Carol Paton, Louise Marston, Linda Davies, William Whittaker, David Osborn, Raj Kumar, Patrick Keown, Rameez Zafar, Khalid Iqbal, Vineet Singh, Pavel Fridrich, Zachary Fitzgerald, Hemant Bagalkote, Peter M Haddad, Mariwan Husni, Tim Amos
Médium: Artigo
Jazyk:Inglês
Vydáno: NIHR Journals Library 2017-09-01
Edice:Health Technology Assessment
Témata:
amisulpride
clozapine
schizophrenia
treatment-resistant schizophrenia
randomised controlled trial
placebo controlled
cost-effectiveness
On-line přístup:https://doi.org/10.3310/hta21490
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky